TSG101 antibody [4A10] is a well-validated and highly cited mouse monoclonal antibody that detects TSG101, a protein of 390 amino acids and a predicted molecular weight of 44 kDa that is a core constituent of the ESCRT-I complex. Reports have described it having both tumor suppressor and tumor enhancer activities. TSG101 is involved in exosome secretion and is commonly used as an exosome marker.
*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
293T , K562 , THP-1 , HL-60 , Neuro 2A , C8D30 , NIH-3T3 , Raw264.7 , C2C12 , NIH-3T3 , JC , BCL-1
Knockdown/Knockout validation was supported by references (PMID:27226592)
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1.8 mg/ml (Please refer to the vial label for the specific concentration.)
Amino acids 167-374 of TSG101 protein expressed in E. coli.
Purified by antigen-affinity chromatography.
From tissue culture supernatant
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
tumor susceptibility 101 , TSG10 , VPS23
Cytoplasm , Nucleus
The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression. [provided by RefSeq, Jul 2008]